利福平脂质体治疗小鼠结核病的初步研究

A Preliminary Investigation of Rifampin liposome in Treatment of Tuberculosis in Mice

目的探讨利福平脂质体在治疗小鼠结核病中的效果。方法昆明小鼠60只,感染结核分枝杆菌标准株H37Rv制备结核模型。利福平用薄膜分散法制备脂质体。小鼠随机分为4组,利福平组[10mg/(kg/d)]和利福平脂质体组[7mg/(kg/d)],口服给药治疗1个月时,牺牲小鼠,观察肺的重量变化,取肺,脾,肝组织进行研磨制匀浆并进行菌落计数。结果利福平组和利福平脂质体组各自分别与正常对照组,空白脂质体组比较发现肺的重量具有显著改变(P<0.01),而两组药物组之间无显著差异(P>0.05)。在肺、脾和肝组织的载菌量(cfu)比较时也显示出同样的情况。结论脂质体制剂可以减少利福平的剂量以减轻不良反应,在结核病的治疗中可能有很好的前景。

Objective To explore the effect of rifampin liposome in treatment of tuberculosis in mice. Methods Sixty KM mice were infected by H37Rv to prepare tuberculosis model. Rifampin liposome was prepared by thin film dispersing method. Mice were ran- domly divided into 4 groups （ 15 mice each） ： group of normal control, empty liposome control, rifampin （ 10mg/kg body weight/day） and rifampin liposome （7mg/kg body weight/day）. Rifampin and rifampin liposome were put into drinking water, respectively. Mice were sacrificed after one month of oral treatment to analysize the difference of lung weight and to homogenize lung, spleen, liver tissues to test bacteria burden （cfu）. Results Lung weight was significantly different in rifampin and rifampin liposome groups when compared with normal control, empty liposome control groups respectively （P 〈 0.01 ）, while no significant difference was found （P 〉 0.05 ） in two drug groups. Things were the same when compared bacteria cfu in lung, spleen and liver tissue. Conclusion Rifampin liposome may become a promising preparation in the treatment of tuberculosis which make it possible to reduce the clinical dose and thus weaken side effects of rifampin.